<\/p>\n
Roliten<\/strong> obsahuje tolterodin tartr\u00e1t<\/strong> \u2014 kompetitivn\u00ed antagonista muskarinov\u00fdch acetylcholinov\u00fdch receptor\u016f pou\u017e\u00edvan\u00fd k l\u00e9\u010db\u011b hyperaktivn\u00edho mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e (OAB)<\/strong> p\u0159i urgentn\u00ed inkontinenci, \u010dast\u00e9m mo\u010den\u00ed a nutkav\u00e9 inkontinenci. K dispozici jako 1 mg tablety s okam\u017eit\u00fdm uvol\u0148ov\u00e1n\u00edm. Standardn\u00ed d\u00e1vka: 2 mg dvakr\u00e1t denn\u011b<\/strong> (nebo 1 mg dvakr\u00e1t denn\u011b p\u0159i ren\u00e1ln\u00ed\/jatern\u00ed insuficienci nebo p\u0159i u\u017e\u00edv\u00e1n\u00ed siln\u00fdch inhibitor\u016f CYP3A4). Pro pohodln\u00e9 jednodenn\u00ed d\u00e1vkov\u00e1n\u00ed s hlad\u0161\u00edm profilem ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f viz forma s prodlou\u017een\u00fdm uvol\u0148ov\u00e1n\u00edm (Terol LA)<\/a>. Tolterodin je obecn\u011b l\u00e9pe sn\u00e1\u0161en ne\u017e oxybutynin<\/strong> \u2014 m\u00e9n\u011b sucha v \u00fastech, m\u00e9n\u011b z\u00e1cpy a ni\u017e\u0161\u00ed penetrace do CNS. U\u017e\u00edvejte opatrn\u011b u dosp\u011bl\u00fdch ve v\u011bku 65+<\/strong> \u2014 krit\u00e9ria Beers 2023 Americk\u00e9 geriatrick\u00e9 spole\u010dnosti klasifikuj\u00ed v\u0161echny anticholinergn\u00ed l\u00e9ky na OAB jako \u201cpotenci\u00e1ln\u011b nevhodn\u00e9\u201d u star\u0161\u00edch dosp\u011bl\u00fdch kv\u016fli kumulativn\u00ed anticholinergn\u00ed z\u00e1t\u011b\u017ei. Mirabegron (Mirago)<\/strong> je preferovan\u00fdm l\u00e9kem prvn\u00ed volby u t\u00e9to populace.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n <\/p>\n Ka\u017ed\u00e1 \u0161ar\u017ee je dod\u00e1v\u00e1na od v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/strong>. Objedn\u00e1vky jsou expedov\u00e1ny v nen\u00e1padn\u00fdch obalech bez loga od na\u0161ich partnersk\u00fdch sklad\u016f a jsou pokryty na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>: pokud z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, za\u0161leme zdarma n\u00e1hradn\u00ed z\u00e1silku, bez dotaz\u016f.<\/p>\n Roliten je zna\u010dka tolterodintartr\u00e1tu 1 mg tablet s okam\u017eit\u00fdm uvol\u0148ov\u00e1n\u00edm<\/strong>. Tolterodin je jedn\u00edm z celosv\u011btov\u011b nej\u010dast\u011bji p\u0159edepisovan\u00fdch antimuskarinik pro l\u00e9\u010dbu hyperaktivn\u00edho mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e. Na mezin\u00e1rodn\u00edm trhu je zn\u00e1m pod obchodn\u00edmi n\u00e1zvy Detrol \/ Detrol LA (US), Detrusitol \/ Detrusitol XL (UK\/EU)<\/strong>. Balen\u00ed dostupn\u00e1 na MedsBase: 30, 60, 90 nebo 180 tablet\/tobolek.<\/p>\n Tolterodin je kompetitivn\u00ed antagonista M2 a M3 muskarinov\u00fdch acetylcholinov\u00fdch receptor\u016f<\/strong>. Blok\u00e1da M3 receptor\u016f v mo\u010dov\u00e9m m\u011bch\u00fd\u0159i sni\u017euje parasympaticky \u0159\u00edzen\u00e9 kontrakce detruzoru b\u011bhem f\u00e1ze pln\u011bn\u00ed \u2013 co\u017e vede ke sn\u00ed\u017een\u00ed urgency a epizod inkontinence a ke zv\u00fd\u0161en\u00ed funk\u010dn\u00ed kapacity mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e.<\/p>\n Ve srovn\u00e1n\u00ed s oxybutynin<\/a>, tolterodin m\u00e1 o n\u011bco lep\u0161\u00ed selektivitu pro mo\u010dov\u00fd m\u011bch\u00fd\u0159 oproti muskarinov\u00fdm receptor\u016fm slinn\u00fdch \u017el\u00e1z, ni\u017e\u0161\u00ed penetraci do CNS a p\u0159\u00edzniv\u011bj\u0161\u00ed profil ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f \u2013 zejm\u00e9na m\u00e9n\u011b z\u00e1va\u017enou suchost v \u00fastech. Oba l\u00e9ky jsou st\u00e1le anticholinergika se standardn\u00edmi varov\u00e1n\u00edmi pro pou\u017eit\u00ed u star\u0161\u00edch pacient\u016f.<\/p>\n Tolterodin je metabolizov\u00e1n CYP2D6 na aktivn\u00ed metabolit (5-hydroxymethyltolterodin), kter\u00fd v\u00fdznamn\u011b p\u0159isp\u00edv\u00e1 k klinick\u00e9mu \u00fa\u010dinku. Asi 5\u201310 % populace jsou \u201cpomal\u00ed metaboliz\u00e9to\u0159i\u201d CYP2D6, kte\u0159\u00ed tvo\u0159\u00ed m\u00e9n\u011b metabolitu a pot\u0159ebuj\u00ed \u00fapravu d\u00e1vkov\u00e1n\u00ed.<\/p>\n Tolterodin m\u00e1 o n\u011bco ni\u017e\u0161\u00ed penetraci do CNS ne\u017e oxybutynin a obecn\u011b je pova\u017eov\u00e1n za l\u00e9pe sn\u00e1\u0161en\u00fd ze dvou anticholinergn\u00edch l\u00e9k\u016f na OAB u star\u0161\u00edch pacient\u016f \u2014 p\u0159esto je podle krit\u00e9ri\u00ed Beers st\u00e1le klasifikov\u00e1n jako \u201cpotenci\u00e1ln\u011b nevhodn\u00fd\u201d a m\u011bl by b\u00fdt pou\u017e\u00edv\u00e1n opatrn\u011b a v nejni\u017e\u0161\u00ed \u00fa\u010dinn\u00e9 d\u00e1vce. Mirabegron z\u016fst\u00e1v\u00e1 preferovanou prvn\u00ed volbou pro l\u00e9\u010dbu OAB u dosp\u011bl\u00fdch star\u0161\u00edch 65 let<\/strong> pokud je dostupn\u00fd a nejsou kontraindikace v podob\u011b hypertenze.<\/p>\n Neu\u017e\u00edvejte tolterodin, pokud m\u00e1te:<\/strong><\/p>\n Pou\u017e\u00edvejte s opatrnost\u00ed, pokud m\u00e1te:<\/strong> vy\u0161\u0161\u00ed v\u011bk (viz v\u00fd\u0161e), benign\u00ed hyperplazie prostaty (riziko retence mo\u010di), refluxn\u00ed ezofagitida, autonomn\u00ed neuropatie, vrozen\u00e9 nebo z\u00edskan\u00e9 prodlou\u017een\u00ed QT intervalu, ischemick\u00e1 choroba srde\u010dn\u00ed.<\/p>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
\n
Co je Roliten?<\/h2>\n
Jak tolterodin funguje<\/h2>\n
Kdy se tolterodin pou\u017e\u00edv\u00e1<\/h2>\n
\n
D\u00e1vkov\u00e1n\u00ed & zp\u016fsob u\u017e\u00edv\u00e1n\u00ed<\/h2>\n
\n
Vedlej\u0161\u00ed \u00fa\u010dinky & bezpe\u010dnost<\/h2>\n
\n
Anticholinergn\u00ed z\u00e1t\u011b\u017e a senio\u0159i<\/h2>\n
Kontraindikace a varov\u00e1n\u00ed<\/h2>\n
\n
Interakce l\u00e9k\u016f<\/h2>\n
\n
Srovn\u00e1n\u00ed tolterodinu<\/h2>\n